Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor

RS Negrin(Stanford University), PL Greenberg(Stanford University), DH Haeuber(Stanford University), Arnon Nagler(Tel Aviv University), Jeffrey Sklar(Stanford University), M. Vincent(Stanford University), Timothy A. Donlon(Stanford University), Yuya Kobayashi(Stanford University)

Blood

July 1, 1990

10.1182/blood.v76.1.36.bloodjournal76136

Cited by 8

Related Papers

Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases

|Blood|1998|1.9k

Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases

|Blood|1998|1.8k

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

|Journal of Clinical Oncology|2013|439

Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia

|Leukemia|2015|216

Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase

|Blood|2002|213